| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 149, 129-142, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
GA Niehans, DL Cherwitz, NA Staley, DJ Knapp and AP Dalmasso
Pathology and Laboratory Medicine Service, Minneapolis Veterans Affairs Medical Center, MN, USA.
Normal human tissues express membrane-associated complement inhibitory proteins that protect these tissues from damage by autologous complement. To determine whether neoplasms also express these proteins, we examined the distribution of the complement inhibitors decay- accelerating factor (DAF), CD59 (protectin), and membrane cofactor protein in frozen samples of human breast, colon, kidney, and lung carcinomas and in adjacent non-neoplastic tissues, using immunohistochemistry. All samples were also studied for deposition of C3 fragments and activated C5b-9. Differences between normal tissues and the corresponding neoplasms were often observed, with loss or gain of expression of one or more inhibitors. Ductal carcinomas of the breast showed the most variation in phenotype; some tumors expressed only one inhibitor while others expressed different combinations of two or three inhibitors. Colon carcinomas, by contrast, stained intensely for all inhibitors. Renal cell carcinomas had weak to moderate expression of one to three inhibitors, generally DAF and CD59, whereas non-small cell carcinomas of the lung usually expressed CD59 and membrane cofactor protein with variable DAF immunoreactivity. The two small cell carcinomas of the lung showed little or no staining for any inhibitor. Activated C5b-9 deposition was seen adjacent to tumor nests in a minority of carcinomas and showed no correlation with complement inhibitor expression. C3 fragment deposition was minimal. Our results demonstrate that most carcinomas, with the exception of small cell carcinomas of the lung, do express one or more complement inhibitors at a level likely to inhibit complement-mediated cellular damage. Unexpectedly, large quantities of DAF and CD59 were often observed in tumor stroma, with only limited deposition in normal connective tissue. This suggests that carcinomas may supplement the activity of membrane- associated complement inhibitors by release of soluble forms of DAF and CD59 into the surrounding extracellular matrix.
This article has been cited by other articles:
 |
|
 |
|
  J. C. Varela, M. Imai, C. Atkinson, R. Ohta, M. Rapisardo, and S. Tomlinson Modulation of Protective T Cell Immunity by Complement Inhibitor Expression on Tumor Cells Cancer Res., August 15, 2008; 68(16): 6734 - 6742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels Clin. Cancer Res., March 1, 2008; 14(5): 1561 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan Combined Yeast {beta}-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55 Cancer Res., August 1, 2007; 67(15): 7421 - 7430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ajona, Y.-F. Hsu, L. Corrales, L. M. Montuenga, and R. Pio Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth J. Immunol., May 1, 2007; 178(9): 5991 - 5998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Higuchi, Y. Endo, H. Suzuki, F. Osuka, Y. Shio, K. Fujiu, R. Kanno, A. Oishi, T. Fujita, and M. Gotoh Identification of the Decay-Accelerating Factor CD55 as a Peanut Agglutinin-Binding Protein and Its Alteration in Non-Small Cell Lung Cancers. Clin. Cancer Res., November 1, 2006; 12(21): 6367 - 6372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Rozanov, A. Y. Savinov, V. S. Golubkov, S. Tomlinson, and A. Y. Strongin Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res., June 15, 2006; 66(12): 6258 - 6263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer Cancer Res., November 15, 2005; 65(22): 10562 - 10568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Allendorf, J. Yan, G. D. Ross, R. D. Hansen, J. T. Baran, K. Subbarao, L. Wang, and B. Haribabu C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis Is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and {beta}-Glucan J. Immunol., June 1, 2005; 174(11): 7050 - 7056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ajona, Z. Castano, M. Garayoa, E. Zudaire, M. J. Pajares, A. Martinez, F. Cuttitta, L. M. Montuenga, and R. Pio Expression of Complement Factor H by Lung Cancer Cells: Effects on the Activation of the Alternative Pathway of Complement Cancer Res., September 1, 2004; 64(17): 6310 - 6318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Gelderman, P. J. K. Kuppen, N. Okada, G. J. Fleuren, and A. Gorter Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model Cancer Res., June 15, 2004; 64(12): 4366 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Madjd, L. G. Durrant, R. Bradley, I. Spendlove, I. O. Ellis, and S. E. Pinder Loss of CD55 Is Associated with Aggressive Breast Tumors Clin. Cancer Res., April 15, 2004; 10(8): 2797 - 2803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Hernandez-Ilizaliturri, V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin's Lymphoma Severe Combined Immunodeficiency Mouse Model Clin. Cancer Res., December 1, 2003; 9(16): 5866 - 5873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Betis, P. Brest, V. Hofman, J. Guignot, M.-F. Bernet-Camard, B. Rossi, A. Servin, and P. Hofman The Afa/Dr Adhesins of Diffusely Adhering Escherichia coli Stimulate Interleukin-8 Secretion, Activate Mitogen-Activated Protein Kinases, and Promote Polymorphonuclear Transepithelial Migration in T84 Polarized Epithelial Cells Infect. Immun., March 1, 2003; 71(3): 1068 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Corey, R. J. Kinders, C. M. Poduje, C. L. Bruce, H. Rowley, L. G. Brown, G. M. Hass, and R. L. Vessella Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis J. Biol. Chem., April 21, 2000; 275(17): 12917 - 12925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. B. Ridgway, E. Ng, J. A. Kern, J. Lee, J. Brush, A. Goddard, and P. Carter Identification of a Human Anti-CD55 Single-Chain Fv by Subtractive Panning of a Phage Library Using Tumor and Nontumor Cell Lines Cancer Res., June 1, 1999; 59(11): 2718 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Varsano, L. Rashkovsky, H. Shapiro, and J. Radnay Cytokines Modulate Expression of Cell-Membrane Complement Inhibitory Proteins in Human Lung Cancer Cell Lines Am. J. Respir. Cell Mol. Biol., September 1, 1998; 19(3): 522 - 529. [Abstract] [Full Text]
|
|
|
|
|
|
V. T. Blok, M. R. Daha, O. Tijsma, C. L. Harris, B. P. Morgan, G. J. Fleuren, and A. Gorter A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and Tumor Cell Lysis by Complement J. Immunol., April 1, 1998; 160(7): 3437 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tieng, C. Le Bouguenec, L. du Merle, P. Bertheau, P. Desreumaux, A. Janin, D. Charron, and A. Toubert From the Cover: Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA PNAS, March 5, 2002; 99(5): 2977 - 2982. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
